Abstract 16288: Analysis of Immunological Function of Infants With Congenital Heart Disease After Cardiopulmonary Bypass Surgery: Evaluation of the Optimum Timing for Vaccination
Background: Infants with congenital heart disease (CHD) after cardiovascular surgeries with cardiopulmonary bypass (CPB) have to resume vaccinations, because the infectious risks of them are reported to be higher than those of healthy children. However, little is known about the timing when vaccination should be resumed. Therefore, in the present study, we examine immunological function of infants with CHD after cardiovascular surgeries with CPB, and determine the optimum timing of vaccination.
Methods: Eleven patients with CHD after cardiovascular surgeries with CPB were examined 2.1 ± 0.7 months after surgeries. The age was 8.4 ± 6.2 months. In order to evaluate humoral immunological function, we measured IgG, IgA, IgM, CD3, CD4, CD8, CD4/8, CD20, and CD56, using flow cytometry method. We also performed lymphocyte transformation test to assess the cell mediated immunological function. And we evaluated the presence of recurrent infections to detect immunodeficiency clinically.
Results: All of data about humoral and cell mediated immunological function were within normal limits (IgG 516.3 ± 227.3mg/dl, IgA 28.0 ± 27.9mg/dl, IgM 72.7 ± 45.4mg/dl, CD3 57.7 ± 14.7%, CD4 38.6 ± 13.1%, CD8 23.5 ± 6.3%, CD4/CD8 1.84 ± 1.2, CD20 21.9 ± 7.4%, CD56 16.4 ± 9.1%, PHA 46118 ± 13896cpm). And we did not recognize focal infection findings and immunodeficiency symptoms. No patient recurred infections.
Conclusions: Both of the humoral and cell mediated immunological function were within normal limits 2.1 ± 0.7 months after cardiovascular surgeries with CPB. These results suggested that the optimum timing of vaccination in infants with CHD was 1month to 3 months after CPB surgery.
- © 2013 by American Heart Association, Inc.